Navigation Links
Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
Date:2/28/2008

trials; manufacturing; regulatory approval requirements and process; the effort and expense necessary for further development of Kosan's product candidates, including the costs of bortezomib; intellectual property matters, including Kosan's ability to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and other risk factors are discussed under "Risk Factors" in Kosan's Quarterly Report on Form 10-Q for the quarter ended September 30, 2007 and other periodic filings with the SEC. Kosan expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.
Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

Selected Financial Information

Condensed Statements of Operations

(in thousands, except per share amounts)

Three Months Ended Year Ended

December 31, December 31,

2007 2006 2007 2006

(unaudited) (unaudited)

Total revenues $5,636 $5,710 $22,707 $13,506

Operating expenses:

Research and development 13,902 8,817 47,283 37,179

General and administrative 2,108 2,090 8,162 7,823

Total operating expenses 16,010 10,907 55,445 45,002

Loss from operations (10,374) (5,197) (32,738) (31,496)

Other income, net 893 638 4,080 2,027

Net loss
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Kosan Announces February 28, 2008 Conference Call and Webcast
2. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
3. Kosan Announces Third Quarter 2007 Financial Results
4. Kosan to Reacquire Epothilone Program From Roche
5. Kosan Biosciences to Host Research & Development Day on October 31, 2007
6. Kosan Biosciences to Present at the Biotechnology Industry Organization Investor Forum
7. Kosan Biosciences to Present at the 2007 UBS Global Life Sciences Conference
8. Kosan Biosciences to Present at the Bear Stearns 20th Annual Healthcare Conference
9. Wyeth Announces Executive Change in Finance Organization
10. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
11. Pharmacopeia Announces Management Team Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... BOSTON , Oct. 22, 2014 /PRNewswire/ ... global specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, ... option to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, ... agonist, for the treatment of diabetic gastroparesis and other ... a successful Phase 2 trial of relamorelin for the ...
(Date:10/22/2014)... The North American crystal oscillator market report ... analysis and forecast of revenue. This market was valued ... reach $623.6 million by 2018, at a CAGR of ... TOC of the North American crystal oscillator market report, ... This also provides a glimpse of the segmentation of ...
(Date:10/22/2014)... October 22, 2014 Involution Studios ... release of a new infographic, Understanding Ebola . ... a beautifully designed, easy to follow informative tool for ... of outbreak, symptoms and prevention. , "As the news ... the 2014 Ebola outbreak represents not only a healthcare ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 ... from Sartorius, A & D Weighing, Rice Lake, ... CPA Semi-Micro Balance . The Sartorius CPA Semi-Micro ... an affordable high-quality, precise, and user-friendly laboratory balance. ... of laboratory equipment, their laboratory balances are well ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3
... Terumo Americas Holding, Inc., a U.S. subsidiary of Japan,s ... manufacturers with $3.4 billion in sales and operations in ... entered into a Stock Purchase Agreement to acquire all ... company working to commercialize the world,s first point-of-care technology ...
... make it possible to improve photoelectrochemical cells. In the ... into energy, these cells use sunlight to drive chemical ... involves using a light-sensitive semi-conducting material such as cuprous ... reaction. Although it is not expensive, the oxide is ...
... 2011 Biocept, Inc., a privately-held laboratory testing ... of circulating tumor cells (CTCs) in cancer patients, ... the identification of different CTC phenotypes using its ... paper, appearing in the Journal of Oncology ...
Cached Biology Technology:Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 2Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 3Terumo Americas Holding, Inc., Agrees to Acquire Harvest Technologies Corporation, a Leader in the Development of Point-of-Care Cellular Therapy 4Harnessing the energy of the Sun: New technique improves artificial photosynthesis 2Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients 2Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients 3
(Date:10/14/2014)... fly genome for the first time, revealing robust immune ... thrives in pathogen-rich dung piles and garbage heaps. , ... Genome Biology , will increase understanding of house fly ... to resist insecticides, which could lead to novel control ... transmit more than 100 human and animal diseases, including ...
(Date:10/14/2014)... new kind of stem cell that can become either a ... according to a study published today in the journal ... type contradicts current theory on how organs arise from cell ... of, and future treatment for, liver cancer., Thanks to stem ... being made up of more than 200 cell types. The ...
(Date:10/14/2014)... LA JOLLA, CA – October 14, 2014 – Scientists ... $6.6 million from the National Institutes of Health (NIH) ... most prevalent virus-induced hemorrhagic fever disease in Africa. The ... disease and why some patients die, while others survive ... researchers to understand the basic mechanism of how Lassa ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2
... pioneering stem cell bandage, believed to be the world,s first ... heal torn meniscal cartilage, can now take the technology to ... the UK,s most successful entrepreneurs. Mr Hugh Osmond, a ... into the UK,s largest sit-down restaurant chain and founded one ...
... The possibility that functional, three-dimensional tissues and organs ... stem cells (ESCs) and induced pluripotent stem cells (iPSCs), ... research, but is also one of the fundamental goals ... has played a central role in informing such efforts, ...
... November 14, 2011 DERMALOG Identification Systems ... a new world record in the identification of fingerprints. ... is capable of correctly identifying the ten fingerprints of ... more than 129 million fingerprints. The renowned international SGS ...
Cached Biology News:World's first stem cell bandage in human clinical trials 2Self-organized pituitary-like tissue from mouse ES cells 2Self-organized pituitary-like tissue from mouse ES cells 3Self-organized pituitary-like tissue from mouse ES cells 4World Record in Fingerprint Identification: DERMALOG Correctly Identifies 129 Million Fingerprints in one Second 2World Record in Fingerprint Identification: DERMALOG Correctly Identifies 129 Million Fingerprints in one Second 3
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
... anti-Human Alpha 1 Acid Glycoprotein ... Goats were immunized with ... in Freund's adjuvant. The ... to ensure specificity. For ...
Biology Products: